Abstract 268P
Background
In early breast cancer, residual disease after neoadjuvant chemotherapy is considered an important prognostic factor, especially for triple-negative breast cancer (TNBC) and HER2-positive patients. The CREATE-X study demonstrated a survival benefit of adjuvant capecitabine (adjC) for these patient groups, particularly in TNBC. Researchers have been trying to find the appropriate population for adjC as Real-World Evidence (RWE). However, RWE in the Asian population was lacking, and previous RWE studies were limited in number. In addition, these studies did not include patients who received neoadjuvant immunotherapy treatment, while the Keynote-522 trial demonstrated the benefit of immunotherapy in early TNBC. Therefore, we evaluated the advantages of adjC in non-pCR TNBC patient group by using RWD.
Methods
We conducted a retrospective analysis of 1,033 TNBC patients who received neoadjuvant treatment at Samsung Medical Center between 2018 and 2023, using de-identified, anonymous data from the institutional Clinical Data Warehouse. Among these patients, we identified 403 patients who received at least one cycle of adjC, while 36 received no adjuvant treatment. Residual Cancer Burden (RCB) classification were available for 399 patients. The primary outcome of the study was Disease-Free Survival (DFS). We conducted a survival analysis using Kaplan-Meier method.
Results
The median DFS has not yet been reached. The disease risk of the adjC group tended to be lower than that of the no adjuvant treatment group, but the difference was not statistically significant (Hazard ratio(HR), 0.52; p-value=0.083). At 36 months, 86% of patients in the adjC group were disease-free or alive, compared to 76% of patients in the no adjuvant treatment group. Compared to the RCB-I group (n=114, 28.4%), the HR for the RCB-II group (n=233, 58.5%) was 1.40, and the for the RCB-III group (n=52, 13.1%), it was 5.88 (p<0.0001). The DFS at 36 months was 90%, 89%, and 67% for the RCB-I, II, and III groups, respectively.
Conclusions
In this study, adjC demonstrated a potential survival benefit for non-pCR TNBC patients. Subgroup analysis based on RCB classification indicated a higher risk associated with higher RCB class.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
This study was supported by Future Medicine 2030 Project of the Samsung Medical Center [SMO1230451].
Disclosure
M.J. Kim: Financial Interests, Personal, Full or part-time Employment: Roche Korea. Y.H. Park: Financial Interests, Personal, Advisory Board: AstraZeneca, Pfizer, Roche, Novartis, MSD, Daiichi Sankyo; Financial Interests, Personal, Invited Speaker: AstraZeneca, Pfizer, Roche, Novartis, MSD; Financial Interests, Institutional, Other, Research Grant: AstraZeneca, Pfizer, Roche, MSD; Non-Financial Interests, Principal Investigator: AstraZeneca, Pfizer, Novartis, MSD, Lilly, Roche, Daiichi Sankyo. All other authors have declared no conflicts of interest.
Resources from the same session
314P - Concordance of somatic variants between circulating tumor DNA and tissue in patients with breast cancer
Presenter: Kangsu Shin
Session: Poster session 02
315P - Multinational survey study assessing genetic testing and counselling among patients (pts) with breast cancer (MAGENTA): Results on perceptions on testing
Presenter: Sarah Powell
Session: Poster session 02
316P - Comprehensive characterization of the HER2-enriched intrinsic molecular subtype in ER-positive HER2-negative breast cancer
Presenter: Lennart Hohmann
Session: Poster session 02
317P - Awareness of genomic testing among patients with breast cancer in Europe
Presenter: Antonella Cardone
Session: Poster session 02
318P - Evaluation of novel diagnostic kits using the semi-dry dot-blot method combined for detecting metastases in sentinel lymph nodes of patients with breast cancer: A multi-center prospective study
Presenter: Ryota Otsubo
Session: Poster session 02
319P - The impact of low HER2 expression on clinical significances and outcomes in patients with HER2-negative early breast cancer
Presenter: Yumiko Koi
Session: Poster session 02
320P - Clinical and pathological characteristics of breast cancers switching from early luminal-like to metastatic triple-negative phenotype
Presenter: Mariia Ivanova
Session: Poster session 02
321P - Non-BRCA variants in hereditary breast and ovarian cancer patients in the northern Mexico population
Presenter: Dione Aguilar
Session: Poster session 02
322P - Clinicopathological characteristics and genomic profiling of pure mucinous breast cancer
Presenter: Shusen Wang
Session: Poster session 02
323P - Macrophage population analysis of the breast cancer microenvironment within the context of seroma formation after mastectomy (SerMa pilot study)
Presenter: Felicitas Schneider
Session: Poster session 02